RxDoctor Payments Data

William McCune, MD

Rheumatology · Ann Arbor, MINPI 1104901610

Payments from drug & device makers

What this record shows

Reporting peaked in 2020 at $1,200 and has fallen 52.1% since, to $575 in 2024. That places this record below the midpoint for rheumatology clinicians in MI, where the typical reported total is $1,854.

$2,400in general payments, 2019–2025

Across 3 payments — averaging $800.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Rigel Pharmaceuticals, Inc.$1K
  • Sanofi US Services Inc.$1K
$157,788in research payments, 2019–2025

Across 34 payments — averaging $4640.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • E.r. Squibb & Sons, L.L.C.$74K
  • GSK$40K
  • Eli Lilly$36K
  • Astrazeneca UK Limited$8K

What the payments were for

  • Consulting fees$1,20050%
  • Speaking & faculty fees$1,20050%

General payments by program year

20
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Rigel Pharmaceuticals, Inc.1$1,200
Sanofi US Services Inc.2$1,200

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,400 in reported general payments places this provider in the 50th percentile of 195 rheumatology providers in Michigan.

See all rheumatology providers in Michigan

Medicare billing

Part B allowed, 2024
$11,719
Medicare patients
67
Services billed
119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BenlystaBelimumab46$214,814
Humira(Cf)Adalimumab13$174,600
Enbrel MiniEtanercept11$113,062
Actemra ActpenTocilizumab13$63,060
OtezlaApremilast11$53,138
EnbrelEtanercept12$42,869
Mycophenolic AcidMycophenolate Sodium11$5,556
Hydroxychloroquine Sulfate108$4,046
Mycophenolate Mofetil19$3,019
Leucovorin Calcium16$2,324
MethotrexateMethotrexate Sodium50$2,275
Prednisone110$2,132
Azathioprine12$642
Gabapentin13$387
Allopurinol12$297

Paid to pharmacies, not to this prescriber.

Other rheumatology in Ann Arbor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →